Evommune, Inc 8-K, filed Dec 11, 2025
Evommune, Inc. (EVMN)
About this 8-K
Evommune, Inc filed this 8-K on December 11, 2025.
Items reported
- Item 2.02: Financial results
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
||
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code: (
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition.
On December 11, 2025, Evommune, Inc. (the “Company”) issued a press release providing a business update and announcing its financial results for the third quarter ended September 30, 2025 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 and is incorporated by reference.
The information in this Item 2.02, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02, including Exhibit 99.1 hereto, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as otherwise expressly stated in any such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
|
Description |
|
||
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Evommune, Inc. |
|
|
|
|
|
Date: December 11, 2025 |
|
By: |
/s/ Luis Peña |
|
|
|
Luis Peña |
|
|
|
President and Chief Executive Officer |
2
Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update
- Three Phase 2 data readouts from lead programs, EVO756 and EVO301, expected in 2026 across atopic dermatitis (AD) and chronic spontaneous urticaria (CSU)
- Well capitalized to deliver on key milestones following completion of initial public offering (IPO), raising $172.5 million in gross proceeds, including the full exercise of the underwriters’ option to purchase additional shares
Palo Alto, Calif., December 11, 2025 – Evommune, Inc. (NYSE: EVMN) (the “Company”), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.
“The recent completion of our IPO puts us in a strong position to deliver on the years ahead, with three Phase 2 readouts across our two lead programs, EVO756 and EVO301, expected next year. Atopic dermatitis (AD) remains the most prevalent autoimmune disease, and the need for more treatment options is urgent. We’re advancing two programs targeting novel mechanisms designed to give physicians and patients new tools to treat AD, if approved. MRGPRX2 antagonism is unique in its potential to change the paradigm as the first target that modulates both mast cells and sensory neurons, and IL‑18 inhibition has the potential to become a front-line biologic target in AD,” said Luis Peña, President and Chief Executive Officer at Evommune. “We also anticipate reporting top-line Phase 2b data from the EVO756 CSU trial in the first half of 2026 and are optimistic that these data will support ongoing development in CSU, which continues to be underserved by existing treatment options and represents a significant market opportunity,” added Mr. Peña.
“Overall, we are energized by the progress and execution across our pipeline, which has broad potential for patients suffering from a range of chronic inflammatory diseases. By identifying and addressing critical gaps in the current treatment landscapes, our team is working diligently to continue to discover and add to the pipeline, with a goal of delivering therapies that provide rapid symptom relief and safe, durable resolution of underlying chronic inflammatory disease,” said Jeegar Patel, Ph.D., Chief Scientific Officer at Evommune.
Pipeline Highlights
EVO756: Potent and highly selective oral small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2), a receptor predominantly found on mast cells and peripheral sensory neurons.
EVO301: Long-acting fusion protein consisting of an IL-18 binding protein and an anti-serum albumin Fab-associated domain with potential for more effective distribution to inflamed tissues than traditional monoclonal antibodies.
Recent Corporate Highlights
In November 2025, the Company completed its IPO of 10,781,250 shares of its common stock at a public offering price of $16.00 per share, including full exercise of the underwriters’ option to purchase additional shares, raising gross proceeds of $172.5 million. Shares began trading on the New York Stock Exchange on November 6, 2025, under the symbol "EVMN."
Third Quarter 2025 Financial Results
About Evommune, Inc.
Evommune, Inc., is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases. The Company’s mission is to improve patients’ daily lives and prevent the long-term effects of uncontrolled inflammation that are a consequence of the limitations of existing therapies. To achieve this, Evommune is advancing a portfolio of differentiated product candidates that target key drivers of chronic inflammation. For more information, please visit www.evommune.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements.” These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of the Company’s product candidates, including the ongoing Phase 2 clinical trials for EVO756 and EVO301; and the expected market opportunity for its lead programs. These forward-looking statements are based on the Company’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company’s clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Many factors may cause differences between current expectations and actual results, including: the Company’s limited operating history and historical losses; the potential that success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; the impacts of macroeconomic conditions, including heightened inflation and uncertain credit and financial markets, on the Company’s business, clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; the Company’s ability to realize the benefits of its collaborations and license agreements; changes in expected or existing competition; changes in the regulatory environment; the Company’s ability to obtain, maintain and protect its intellectual property; and unexpected litigation or other disputes. Other factors that may cause the Company’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading “Risk Factors” in the Company’s final prospectus for its initial public offering, filed with the SEC on November 6, 2025, and in other filings that the Company makes and will make with the SEC in the future. The Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.
Evommune, Inc. |
|
|||||||||||||||||||
Unaudited Condensed Consolidated Statements of Operations |
|
|||||||||||||||||||
(in thousands, except share and per share data) |
|
|||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
|
Three Months Ended |
|
|
Nine Months Ended |
|
||||||||||||||
|
|
September 30, |
|
|
September 30, |
|
||||||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||||||
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
License revenue |
|
$ |
|
10,000 |
|
|
$ |
|
— |
|
|
$ |
|
13,000 |
|
|
$ |
|
7,000 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Research and development |
|
|
|
19,639 |
|
|
|
|
13,289 |
|
|
|
|
53,639 |
|
|
|
|
46,413 |
|
General and administrative |
|
|
|
3,689 |
|
|
|
|
3,228 |
|
|
|
|
10,716 |
|
|
|
|
9,146 |
|
Total operating expenses |
|
|
|
23,328 |
|
|
|
|
16,517 |
|
|
|
|
64,355 |
|
|
|
|
55,559 |
|
Loss from operations |
|
|
|
(13,328 |
) |
|
|
|
(16,517 |
) |
|
|
|
(51,355 |
) |
|
|
|
(48,559 |
) |
Total other income, net |
|
|
|
853 |
|
|
|
|
601 |
|
|
|
|
10,758 |
|
|
|
|
2,477 |
|
Net loss |
|
|
|
(12,475 |
) |
|
|
|
(15,916 |
) |
|
|
|
(40,597 |
) |
|
|
|
(46,082 |
) |
Net loss attributable to common stockholders |
|
|
|
(12,475 |
) |
|
|
|
(15,916 |
) |
|
|
|
(40,597 |
) |
|
|
|
(46,082 |
) |
Basic and diluted net loss per share of common stock |
|
$ |
|
(8.07 |
) |
|
$ |
|
(10.47 |
) |
|
$ |
|
(26.36 |
) |
|
$ |
|
(30.69 |
) |
Weighted average basic and diluted shares of common stock outstanding |
|
|
|
1,545,010 |
|
|
|
|
1,520,814 |
|
|
|
|
1,540,243 |
|
|
|
|
1,501,635 |
|
Evommune, Inc. |
|
|||||||||
Unaudited Condensed Consolidated Balance Sheets |
|
|||||||||
(in thousands) |
|
|||||||||
|
|
|
|
|
|
|
|
|
||
|
|
September 30, |
|
|
December 31, |
|
||||
|
|
2025 |
|
|
2024 |
|
||||
Cash, cash equivalents and short-term investments |
|
$ |
|
76,062 |
|
|
$ |
|
72,040 |
|
Other current assets |
|
|
|
5,879 |
|
|
|
|
1,948 |
|
Other non-current assets |
|
|
|
2,603 |
|
|
|
|
2,067 |
|
Total assets |
|
$ |
|
84,544 |
|
|
$ |
|
76,055 |
|
|
|
|
|
|
|
|
|
|
||
Current liabilities |
|
$ |
|
10,416 |
|
|
$ |
|
27,981 |
|
Other non-current liabilities |
|
|
|
261 |
|
|
|
|
535 |
|
Total liabilities |
|
|
|
10,677 |
|
|
|
|
28,516 |
|
Convertible preferred stock |
|
|
|
257,004 |
|
|
|
|
191,776 |
|
Total stockholders’ deficit |
|
|
|
(183,137 |
) |
|
|
|
(144,237 |
) |
Total liabilities, convertible preferred stock, and stockholders’ deficit |
|
$ |
|
84,544 |
|
|
$ |
|
76,055 |
|
Contacts:
Media:
Paul Laland
Paul.laland@evommune.com
Investors:
Sarah McCabe
investors@evommune.com